Patents Assigned to British Biotech Pharmaceuticals, Ltd.
  • Publication number: 20100125075
    Abstract: Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(?O) or the formula: —C(?O)NH(OH); R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(?O), a hydroxy, C1-C6 alkoxy, C1-C6 alkenyloxy, amino, C1-C6 alkylamino, or di-(C1-C6 alkylamino group; R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-group; and A represents a group of formula (IIA), or (IIB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 when taken together with the nitrogen atom to which they are attached form a saturated heterocyclic first ring of 5 to 7 atoms as specified in the description.
    Type: Application
    Filed: December 14, 2006
    Publication date: May 20, 2010
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Lisa Marie Pratt, Kenneth Noel Keavey, Gilles Denis Pain, Laurent Mounier
  • Publication number: 20090069322
    Abstract: Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(?O) or formula C(?O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or except when Z is a radical of formula —N(OH)CH(?O), a hydroxy, halo or amino group; R2 represents a group R10—(X)n-(ALK)m— wherein R10, ALK, X, m and n are as defined in the specification; R3 represents hydrogen, (C1-C6) alkyl or phenyl(C1-C6)alkyl-; and R5 and R6 are as defined in the specification.
    Type: Application
    Filed: September 26, 2006
    Publication date: March 12, 2009
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Paul Raymond Beckett, Steven Launchbury, Gilles Pain, Lisa Marie Pratt
  • Patent number: 7323448
    Abstract: Compounds of formula (I) or a pharmaceutically or veterinarily acceptable salts thereof wherein R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10-(ALK)m-, and A represents (i) a group of formula (IA): wherein the compounds inhibit the activity of bacterial PDF enzyme.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: January 29, 2008
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
  • Patent number: 7323563
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 29, 2008
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Paul Raymond Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
  • Patent number: 7148198
    Abstract: A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for the inhibition of activity of bacterial PDF enzyme: wherein A represents a group of formula (IA) or (IB) and wherein R1 is hydrogen, R2 is n-butyl, benzyl or cyclopentylmethyl, R3 is hydrogen, R4 is tert-butyl, iso-butyl, benzyl or methyl, R5 is hydrogen or methyl and R6 is methyl.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: December 12, 2006
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
  • Publication number: 20060276409
    Abstract: Compounds of formula (I) are antibacterials: wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are independently 0 or 1; and A represents a group as defined in the specification.
    Type: Application
    Filed: August 2, 2006
    Publication date: December 7, 2006
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael Hunter, Raymond Beckett, John Clements, Mark Whittaker, Stephen Davies, Lisa Pratt, Zoe Spavold, Steven Launchbury
  • Publication number: 20060211732
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:
    Type: Application
    Filed: August 22, 2005
    Publication date: September 21, 2006
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Raymond Beckett, John Martin Clements, Mark Whittaker, Zoe Spavold
  • Patent number: 6992190
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: January 31, 2006
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Paul Raymond Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
  • Publication number: 20050065095
    Abstract: Compounds of formula (II) are antibacterial agents wherein Q represents a radical of the formula: —N(OH)CH(?O) or the formula: —C(?O)NH(OH); R1 represents hydrogen, C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of the formula: —N(OH)CH(?O), a hydroxy, C1-C6 alkoxy, C1-C6 alkenyloxy, amino, C1-C6 alkylamino, or di-( C1-C6 alkyl)amino group; R2 represents a substituted or unsubstituted C1-C6 alkyl, cycloalkyl(C1-C6 alkyl)- or aryl(C1-C6 alkyl)-group; and A represents a group of formula (IIA), or (IIB) wherein R4 represents the side chain of a natural or non-natural alpha amino acid, and R5 and R6 when taken together with the nitrogen atom to which they are attached form a saturated heterocyclic first ring of 5 to 7 atoms as specified in the description.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 24, 2005
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Lisa Pratt, Kenneth Keavey, Gilles Pain, Laurent Mounier
  • Publication number: 20050014702
    Abstract: Compounds of formula (I) are antibacterials: wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are independently 0 or 1; and A represents a group as defined in the specification.
    Type: Application
    Filed: July 29, 2004
    Publication date: January 20, 2005
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael Hunter, Raymond Beckett, John Clements, Mark Whittaker, Stephen Davies, Lisa Pratt, Zoe Spavold, Steven Launchbury
  • Patent number: 6790834
    Abstract: Compounds of formula I are disclosed wherein R4 is an ester or thioester group, and R, R1, R2, and R3 are as defined in the specification are inhibitors of rapidly dividing tumor cells.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: September 14, 2004
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Drummond
  • Patent number: 6545051
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterial effective dose of a compound of formula (I): wherein R1 represents hydrogen, hydroxy, amino, methyl, or trifluoromethyl; R2 represents a group R10—(X)n—(ALK)— wherein R10 represents hydrogen, a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages; X represents —NH—, —O— or —S—, and n is 0 or 1; R represents hydrogen or C1-C6 alkyl; R3 represents the characterising group of a natural or non-natural &agr; amino acid in which any functional groups may be protected; and R4 represents an ester or thioester group.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: April 8, 2003
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker
  • Publication number: 20030050310
    Abstract: Compounds of formula (I) are matrix metalloproteinase inhibitors wherein X represents a carboxylic acid group —COOH, or a hydroxamic acid group —CONHOH;R2 represents a radical of formula (II): R3—(ALK)m—(Q)p—(ALK)n—, and W represents a cyclic amino radical of formula (IIIA) or (IIIB): 1
    Type: Application
    Filed: September 12, 2002
    Publication date: March 13, 2003
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventor: Fionna Mitchell Martin
  • Patent number: 6503897
    Abstract: Compounds of formula (I) are antibacterial agents wherein: R3 and R4, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms, which may be benz-fused or fused to a second optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 atoms; and R1 and R2 are as defined in the specification.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: January 7, 2003
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Raymond Paul Beckett, Mark Whittaker, Zoe Marie Spavold
  • Publication number: 20020198241
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 1
    Type: Application
    Filed: June 26, 2002
    Publication date: December 26, 2002
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Paul Raymond Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
  • Patent number: 6495597
    Abstract: Compounds of formula (I) wherein R4 is an ester or thioester group and R, R1, R2 and R3 are as defined in the specification, inhibit proliferation of tumor cells.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: December 17, 2002
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Andrew Paul Ayscough, Lisa Marie Pratt, Alan Hastings Drummond
  • Publication number: 20020165167
    Abstract: Compounds of formula (I) are antibacterials: 1
    Type: Application
    Filed: April 30, 2002
    Publication date: November 7, 2002
    Applicant: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
  • Patent number: 6462023
    Abstract: The present invention provide compounds exemplified by 2(R or S)-[2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methyl-pentanoylamine]-2-phenyl-ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-phenylethanoic acid isopropyl ester; 2(R or S)-[2R-(S-Hydroxycarbamoyi-methoxy-methyl)-4-methyl-pentanoylamino]-3-phenylethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(4-methoxyphenyl)ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-2-yl)ethanoic acid cyclopentyl ester; and 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-3-yl)ethanoic acid cyclopentyl ester are cytostatic agents. Methods of treating proliferative cell growth disorders as well a methods of inhibiting hyper-proliferative cells are also disclosed.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 8, 2002
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Lindsey Ann Pearson, Andrew Paul Ayscough, Philip Huxley, Alan Drummond
  • Patent number: 6423690
    Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n—(ALK)m— wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: July 23, 2002
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
  • Patent number: 6329373
    Abstract: A compound of formula (I) wherein X is a —CONHOH group and the R groups are defined in the claims. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation and inhibitors of the release of tumour necrosis factor from cells.
    Type: Grant
    Filed: January 7, 2000
    Date of Patent: December 11, 2001
    Assignee: British Biotech Pharmaceuticals, Ltd.
    Inventors: Fionna Mitchell Martin, Christopher Norman Lewis, Mark Whittaker